Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
08 Januar 2010 - 9:23PM
PR Newswire (US)
DURHAM, N.C., Jan. 8 /PRNewswire-FirstCall/ -- Oxygen
Biotherapeutics, Inc. (OTC:OXBT) (BULLETIN BOARD: OXBT) announced
today that its common stock has been approved for listing on the
NASDAQ Capital Market. "Moving up from the OTC Bulletin Board to
the NASDAQ is a very important milestone for our company," said
company chairman and CEO Chris J. Stern. "Being listed on the
NASDAQ provides us with greater visibility for our company, more
liquidity for our stock and the opportunity to further expand our
investor base. I believe that this move will deliver increased
value for our shareholders now and down the road." Trading on the
NASDAQ is excepted to begin next week. The company will announce
further details in due course. Prior to the listing change, Oxygen
Biotherapeutics, Inc. shares will continue to trade on the
Over-the-Counter (OTC) Bulletin Board. About Oxygen
Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is dedicated to
commercializing innovative pharmaceuticals and medical devices in
the field of oxygen therapeutics and Defense Medicine(TM). The
company has developed a perfluorocarbon (PFC) therapeutic oxygen
carrier and liquid ventilation product (Oxycyte(TM)) and has
out-licensed an implantable glucose sensor. These products are
based upon core technologies that include biomedical applications
for PFCs as well as medical and industrial applications for
biosensors. Each of the product candidates is designed with
advantages over currently marketed products in major markets
including traumatic brain injury, sickle cell crisis, trauma, wound
care, decompression sickness, acute respiratory distress syndrome,
stroke, myocardial infarction, surgery, diabetes wounds and ulcers,
and cosmetic applications which are being marketed under the
Dermacyte name. More information is available at
http://www.oxybiomed.com/. DATASOURCE: Oxygen Biotherapeutics, Inc.
CONTACT: Abe Wischnia of Abe Wischnia & Associates,
+1-619-795-2345, for Oxygen Biotherapeutics, Inc. Web Site:
http;//http://www.oxybiomed.com/
Copyright